MeiraGTx Holdings plc (MGTX)

NMS – Real Time Price. Currency in USD

12.11

+0.58 (5.03%)

At close: Jun 26, 2026, 4:00 PM EDT

12.11

-0.00 (-0.00%)

After-hours: Jun 26, 2026, 4:34 PM EDT

05.06.2026

MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

15.05.2026

MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

14.05.2026

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).

14.05.2026

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates

MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.51 per share a year ago.

14.05.2026

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) Strengthened balance sheet with $100 million financing LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2026, and provided a corporate update. “Our achievements in the first few months of 2026 have materially strengthened MeiraGTx – we are now in a position to file for potential approval and launch two wholly-owned therapies in the next 2 years,” said Alexandria Forbes, Ph.D.

05.05.2026

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know

MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

20.04.2026

MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?

MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Videos

No Data

There is no data to display

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx.

16.04.2026

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in bota-vec for the treatment of XLRP.

MeiraGTx Holdings plc (MGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MeiraGTx Holdings plc (MGTX)

MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know

MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?

Videos

No Data

Press releases

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know

MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?

Videos

No Data

Press releases

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Search stocks

MeiraGTx Holdings plc (MGTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MeiraGTx Holdings plc (MGTX)

MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know

MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?

Videos

No Data

Press releases

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript

MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know

MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?

Videos

No Data

Press releases

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)